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ill
Since the completion of the Canadian Multi-centre Post-term Pregnancy Trial. there has
been an increase in the number of inductions of labour at term and beyond term. ln many
centres. the induction of labour rate exceeds 20% of all deliveries.
Concomitant with this increase in induction rates has been an increase in the use of
vaginal prostaglandin primarily dtncprostcne. to aid in pre-induction cervical ripening and
induction of labour. Dinoprostone has been administered by the oral route in the past. but
because of unacceptable gastrointestinal side effects. it's use has been widely abandoned and
replaced by its vaginal administration.
Because of the high costs and limited administration route of dinoprostone. in recent
years attention has turned world-wide to the use of another prostaglandin. "misoprostol". in the
induction of human labour at term. This medication. initially designed for the treatment of upper
gastrointestinal ulcers has been shown 10 be an effective agent for induction of labour. when
administered vaginally.
The purpose of the trial described in this thesis is to evaluate the efficacy and safety of
oral administration ofmisop rostol in induction of labour. when compared to standard methods of
induction. Two groups of patients were formed by random assignation. The first are a control
group who received standard care at our unit for induction of labour at term. Standard care for
these patients would usually include vaginal prostaglins and/or oxytocin. The second group was
the study group. This group received oral misoprostol as the induction of labour agent. The two
groups are then compared for both primary and secondary outcome measures. The primary
outcome measure is the length of lime from commencement of the induction process until
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delivery. Secondary outcome measures compared between the two groups include multiple
parameters of neonatal and maternal morbidity. Finally we were also interested in the
acceptability of oral misoprostol for induction of labour as no other prostaglandin induction
agent has been shown to have an acceptable side effect profile when administered orally. We
therefore also compared labour and delivery maternal satis faction scores between the two groups.
This proved to bea negative trial. There were no statistically significant difference in the
primary outcome measure (time for induction of labour until delivery) or in any of the secondary
outcome measure figures of neonatal or maternal morbidity or maternal satisfaction.
The thesis will be presented in five chapters. The first chapter (Introduction) will provide
an overview of why and how induction of labour has been carried out from historical time until
the presenl for the reader new to this area. In the second chapter (Background) a detailed
discussion of the role of prostaglandin in the induction of labour will be presented. This
background concerning prostaglandin will be narrowed down to a review of the role of a specific
prostaglandin (misoprostol) up to the point where this trial started. To conclude this chapter the
rational behind the decision to study oral misoprostol use would be presented. In chapter three
(Methodology) the exact research question will be specified. The design we chose to attempt to
answer this question will also be described. The very important issues of sample size estimation
and justi fication will then be presented prior to a description of the execution of the design in
terms of the description of the institution where the study was performed ethics in content,
patient recruitment issues etc. In chapter four (Data Analysis) I will present the results of the
trial for both primary and secondary outcomes. Levels of statistical significance will also be
presented. Finally in chapter five (Discussion and Conclusions) will provide a discussion of the
v
strength and weaknesses of the study and its implications for practice. Conclusions which may
reasonably be drawn from this trial will be presented along with the limitations of these
conclusions. Directions for future studies will then bebriefly addressed.
Following the body of the text there will be a full set of appendices illustrat ing me
documentation usedin me study prior 10 me bibliography andreferences .
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CHAPTER I ' INTROQJICTION
1.1 Induction. Labour. Cervical Ripening
The process whereby labour is begun by medical intervention. prior to its spontaneo us
occurrence. is known as " induction of labour" . The indications for induction of labour fall into 2
categories: materna l and fetal." Maternal indications for induction of labou r include any
medical/obstetrica l complication where terminat ing the pregnancy also terminates or lessen the
risk to a pregnant woman. The classic example of a maternal indication for induction of labour is
that of pre-eclampsia, where marked maternal vasa -constriction occurs through.an as yet
undefi ned process. which can produce life threatening secondary changes and it persists until
deli very of the fetus and its placenta. Other maternal indications for delivery include:
antepartum haemorrhage. uncontrolled diabetes. and chorioamn ionitis. Fetal indications for
induction of labour include any circumstance where it is felt that delivery of the fetus would
provide a healthier environ ment for its development and growth. than rema ining in-utero . the
classic example being that of pest-dates. Tradi tionally. post-dates of pregnancy were felt by the
majori ty of obstetrical caregivers to include any pregnancy of 42 weeks duration or longe r.
Other fetal indications for delivery include ultrasound diagnosed fetal growth restrict ion. reduced
amniotic fluid volume and insufficient blood flow through the umbilical cord .
Since the completion of the Canadian Multi-centre Post-term Pregnancy Trial. U many
caregivers now recommend consideration of induction of labour one week after the due dale (41
weeks gestation). As a result of this. induction of labour has increased in Cana da and now
accoun ts for in excess of 20010 of deliveries in many centres. In order to be successfu l. induction
of labour must result in adequate uterine contrac tions and progressive dilatat ion of the uterine
cervix. The total amount of uterine contractility required to achieve cervical dilatation is very
dependent on the state of the cervix. A finn and rigid cervix may require a total quantity of
uterine work that is many times greater than that needed when the cervix is softer and more
yielding. " '6
The consequences of this for the induction of labour have been known for a long time.
Virtually all reports on induction emphasise that the state of the cervix is the most important
predictor of success.
Realisation of the importance of the state of the cervix for induction has led to the
development of various methods to assess cervical "ripeness" (and their use to predict the
outcome of induction) and also the search for methods that decrease cervical resistance prior to
induction.
1.2 Assessment or the eervtx
The cervix is a dynamic structure that undergoes many changes, particularl y in late
pregnancy.'" Along with biochemical changes in the proteoglycan matrix and collagen
degradation, there is an increase in vascularity, an accumulation of interstitial fluid and migration
of white cells and macrophages into the cervical tissue.I""These changes lead to changes in the
biophysical characteristics ofth e cervix in that they cause a greater compliance and less
resistance to dilatation . The increase in compliance is most readily recognised in the differences
to palpation between the firm. rigid cervix at the beginning of pregnancy and the soft,
oedematou s cervix palpated at term.I"" Several cervical scoring systems have been developed in
an attempt to establish guidelines for cervical assessment. The best known of these is the score
proposed by Bishop (1964),20which rates five different qualities (cervical e ffacement, cervica l
dilatation, cervica l consistency, position of the cervix relative to the axis of the pelvis and
descent of the fetal present ing part) on a total score from 0 to I) (Appendix I) .
1.3 Histor ical Review Of Method s Of Labour Induc tion Developments Prior
To Tb e Twentieth Century
Attempts to induce or augment labour have a long history. Induction of labour was
mentioned by Soranos of Ephesus in the second century AD.'s In the ninth and tenth centuries.
Arab physicians described instruments for labour induction.t" In the sixteenth century, Pare and
Guillemeau induced labour in cases of severe uterine haemorrhage."! Eucharius Rodion gave a
list of substances believed to facilitate labour (in the earliest printed obstetric textbook). These
preparations were ingested by women but Rodion also describes packing the genital tract with
wool cloth soaked with the extracts of the Ruta graveolens and Aristolochia sp.!"
The medical history of labour induction really starts in the 18th century. in 1756. when
Macauley induced labour before term in order 10avoid the hazards of both caesarean section and
fetal extraction with the crochet."
Developments during tbe twentieth century
An entirely new approach to labour induction was proposed by Benjamin Watson in
1913.1• .101 Watson called this method "medical induction" to distinguish it from surgical
intervention and it involved administering castor oil and quinine. The modem era of labour
induction began in 1928 with the clinical introduction of purified posterior pituitary extract for
medical induction which subsequently became established in 1955. when synthetically prepared
oxytocin was made available commercially." At first. highly diluted solutions ("the oxytocin
drip'') were used. By 1968. intravenous infusions of escalating doses ("titrated" against uterine
contractions) were introduced by Turnbull and Anderson (l968) '~ to reduce the rate of failed
induction after amniotomy.
Since 1968.9<1>100oxytocin has had a rival for labour induction-the prostaglandins. After
Karim first reported success with intravenous infusion of prostaglandin F1« both this compound
and prostaglandin E, have been used widely for this purpose. Due to the unique effect of
prostaglandins on the uterine cervix. they represent an excellent option for women who. on
account of their unfavourable cervix. are poor candidates for induction using oxytocin.
Furthermore. because prostaglandins are effective when administered either locally or
systemically. local administration has the advantage of requiring much. lower doses of
prostaglandin and avoids the problem of untoward side effects provoked by intravenous
prostaglandin administration. The recent commercial availability of stable preparations of PGE2,
mainly vaginal tablets and gels. has boosted the clinical use of prostaglandins both for priming
the cervix and for inducing labour.
CH APT E R II . BACKGR OUND
2.1 Prost agland ins
The development of the prostagland in method of labour induction has a long history. The
oxytocic properties of these substances had been known long before the prostag landins were
identified as such. In 1930. Kurzrock and Lieb. demonstrated the uterotonic effects of fresh
human semen in vitro. ur. Substances capable of provoking contract ion of smoo th muscle fibres
were found in seminal fluid. by Goldblan in 1933 and Von Euler 1934.11u Von Euler named
these substances "prostaglandins: ' Bergstrom and Sjovall isolated the first prostagland in
(PGF ,..) in 1 957' ~ and in 1964;1' the biosynthesis of several uterotonic prostaglan dins was
achieved. However the obstetric breakthro ugh resulted from the work of Pickles. ' ~ ' who in
1959. had postulated that dysmenorrhoea wascaused by the presence in the menstrua l fluid of a
potent utero tonic substance which he named "menstrual stimulant" . Six years lata he ident ified
this to be a mixture of prostaglandins E and F. Karim.1'" noting a similarity between "u terine
colic" and labour pain. isolated PGE: and PGF~ in amniotic fluid and showed that the
concentratio n of these substances increased durin g early labour. In 1968. Karim announc ed the
successfu l induction of labour at term by cons tan t-dose intravenous infusion of PGF ~.., In 1969.
Embrey suggested that equipotent doses of PGE: were equally useful for elect ive induction of
labour....
2.2 The Present Role Of Pro staglaodios 10The Iudncrtcn or Labour.
Prostag landins are known to play an important role in the physiology of human labour
and it is likely that a late step in the com plicated series of events preceding the onset of labour is
an increase in the endogenous local release of these substances . ~ J7,.O'U) Most of the early clinical
research was conducted with PGF~.., because it was thought to have more uterotonic activity and
because of me initial "shelf instability" of PGE~ . ''''9 Since me early 1970's , a large number of
controll ed evaluations of prostaglandins for inducing labour have been conducted, studying
issues of efficacy, diffe rent vehicles and routes of administration . ~7:~'ul.&' ,~~ ,~ ' , ,,,, . , l).l At first. these
invo lved contro lled comparisons betwee n intravenous prostaglandins and intraveno us oxytocin.
Later, with the advent of othe r routes of prostag landi n administratio n. the controlled comparisons
have been with placebo treatments . with intravenous and buccal oxytocin and between diffe rent
routes and doses of prostaglandins.
2.2.1 Compariso ns with Placebo
Seven studies. all conducted between 1978 and 1984, have compared prostaglandins
(administered in various doses, formulations and routes) with placebo treatments that were
identical except for the added prostaglandin. The "failure" rate of induction and the proportion
of women needing a second induction attempt were statistica lly significantly lower following
prostagland in administration in all of the trials that provided data on these outcomes. I""
2.2.2 Int ravenous, Vaginal and Ora l Adminis tration
Early studies of prostaglandi ns for the induction of labour used the intravenous route of
administratio n.":"..ll:!l,Il.\O~.lQ1 Compared with oxytocin they appeared to offer no advantage and
were considerably more expensive. They tended to produce bothersome side-effects, mainly
vomiting and diarrhoea (which were particularly prominent with PGF:~ ). but also hypothermia
(especia lly with the use of PGE~), Finally, they appeared to require an even more care ful
determination of the infused dose than oxytocin, because of the small margin between doses that
would stimulate uterine contractions adequately and those that would cause "hyperstimulation".
Probably the most widely adopted mode of administration ofP GE: (and PGG:. in
countries where PGE: lis not available), has become the vaginal route.:" Compared with
placebo. vaginal prostaglandins have been shown to achieve shorter time to delivery and a higher
change of spontaneous vaginal delivery. The proprietary compounds "Prepidil" and "Prostin"
are now extremely widespread in their use.
In 1971. Karim and Sharma" reported on the oral administration ofPGE: for induction .
From then on. oral administration of PGE~ ( in doses increasing from 0.5 to 2 mg) became widely
used as an alternative to intravenous infusions of prostaglandins for inducing labour. particularl y
when combined with amniotom y and in women with a favourable cervix, Thiery and his
colleagues (1977) ,16J in a randomized controlled comparison involving 50 women, showed that it
was not necessary for the prostag landin tablets to be swallowed : there were no differences
detected in any of the outcome measures between the 2S women who received PGE~ orally in
doses of 0.5 to 3 mg. and the 25 women who were instructed 10 let the tablets melt away under
the tongue .
Beca use of its gastroi ntestinal side-effects. PGF!1I" is entirely unsuited for oral
administration. However , gastroin testinal side-effects also occur with oral PG~.""·61.n.;"I. .!
Theseside-effects have beenreported to affect between 20 and 50 per cent of women, depend ing
on the doses used. In other controlled comparisons, however . the incidence of gastro intestinal
side-effects with oral PG~ hasbeen reported to be approx imately 10 per cent. ' !.. I ..... ..,
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2.2.3 Pros tag landi ns for Ce rvica l Ripe ning
A few years after the introduction of prostaglandins for inducting labour in the late 196Os,
doses which by themselves were insufficient to induce labour successfully were found to effect a
marked softening of the uterine cervix.J1.lI'l.III .111 This phenomenon is not only observed at term :
marked cervica l softening and changes in the shape of the lower uterine pole are phenomena that
are well known to those experienced with pros taglandin-induced terminations of pregnanc y in
the 2-.1 trimester .Jj·""""'1.lI'I In experimental animals it has been shown that this softenin g results
from a direct effect of prostaglandins on the cervix, which need not be mediated by uterine
contractilit y (Liggins 1978),11) and there is now a substantial body of evidence on the influence
of both endogen ous and exogenous prostag landins on biochemica l and biophysical
characteristics of the cervix.
The occasional need to induce labour in the presence ofan unripe cerv ix requires
methods that have not only been shown to increase cervical compliance. but which increase the
likelihood of spontaneous vaginal delivery of a healthy baby within a reasonable period of time.
Of the various interventions used. only the prostaglandins . which have also been the most
extens ively studied, have so far approached this goal. Use ofprostag!andins in these
circumstances decreases the likelihood of " failed induction", decreases the incidence oflabour
lasting more than 12 and more than 24 hours . and increases the chance'Sofa spontaneous vaginal
deHvery.n .l Ool.l ll ,111
11
2.2.4 Hazards of Prostag landin Admin istratio n
The speci fic hazards attribu table to prostag land ins per se relate mainly to thei r effect s on
the gastro intestinal trac t. predominantly nausea, vomiting and diarrh ea."',ll.lw The sma ll number
of placebo-controlled tria ls of prostag landins for induction of labour provides little eviden ce o f
these effects.':":':" Important additional evidence. howeve r. is avai lable from the larger number
of tria ls in which prostaglandins have been compared with oxytocin for the induction of
labour.lu l.87.61.11I.H1These effec ts are minimal when the drugs are administered endo-cervically or
extra-amniot ically. and maximal when routes of administrat ion (intravenous . oral, and vag ina l)
are used that lead to high levels of these drugs in either the blood or the gastro intestinal tract.
Pyrexia also results from a direct effect of prostaglandins on thenno -regu lating centres in
the brain.J1.:I.u .'I'I Th is is part icularly a problem of prostag landin El admi nistration and may give
rise to concern that intrauterine infection has supervened. This concern may be further fuelled by
a rise in the leukocyte co unt. whic h can also be stimulated by prostaglandin administratio n. If
the membranes are intac t and labour has been of re lative ly short durati on however. pyrex ia is
almost always due to an effect of prostag landin E~ rather than to incipie nt uterine infection .
Important though it is to consider the specific hazards of prostaglandins. it should not be
forgotten that they pale into insigni ficance when considered against the far more worryi ng
complication of uterin e hypert onicity andlo rpolysystole .J9·$ol·lll) In a sma ll number of patients.
equal doses of prostaglandins may have a more potent effec t on uterin e activity than that in the
general popu lation . In these patients excessive uterine contraction may lead to fetal hypoxemia
with subsequent possible fetal hypoxic brain damage and/or death.P
Due to the high costs of these preparations and occasio nal dissatisfaction with their
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effectiveness (in particular with that of Prepidil), investigators have been evaluating other
prostaglandins with regard to their effectiveness and safety in the induction of labour." One of
these prostaglandins is muoorostol which is a prostaglandin E( analogue, produced by Sear le in
its proprietary form as Cytotec·.1.... It is used primarily for prophylaxis against non-stero idal anti-
inflammatory induced upper gastrointestinal comptications." .•' .....l lo .IH.( .... In 1993. Sanchez-
Rarnoz"! demonstrated the effectiveness ofmisoprostol in a randomized trial versus oxytocin for
the induction of labour at term. Since that time. there have been many publications evaluating
the use ofmisoprostol both for induction of labour at term and also for termination of pregnancy.
(See section 1.6).
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2..3 The Bioc:bemistry and Pbannacologic:Actions or Misoprostol:
CHEM ISTRY''''
\1 01«911[ Strprturc'
Cn,
o
......~_CII,
CII, 0
o
Hi ou
Molecu lar Weigh t 382.5
Chemical Name : (+)methy l( l la. 13E)I6-d ihydroxy-16methy l.9-o:<oprost-13.en-I-oate
Description: Misoprostol is a novel synthetic:prostag landin E, analogue . It is a light yellow.
viscous liquid with a musty odour.
Miscprcsrct is rapidly absorbed following oral admi nistration with peak serum levels
ccc urring in about 30 minutes .I '" It is rapidly de-esterfied 10 misoprosto l acid and no intact
misoprosto l remains in plasma . The de-esteri fied metabolite which is the primary biologically
active material undergoe s further metabolism by beta and omega oxidation which takes place in
numerous tissues in the body .l'" The elimination. hal f life subsequently is L7 hours.
Approx imately 60"/. is excreted by the kidney and 4QO!. through feces. I'" In animal studies. there
has beenno evidence o f embryo-toxicity . feto-tc xiciry or teratcgemcity even at extrem ely high
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doses (10,000 mgfkg). Concemsll~ I .~2cIUHI.7Ul regarding teratogenicity of failed first trimester
terminations are presently being prospectively evaluated by the World Health Organization.
In the stomach, the anti-ulcer activity of miscprostol appears to be exerted by histamin e
receptor activation and the formation of cyclic AMP. 1.1-1 The daily recommended dose in adults is
800 rpg in 2 or 4 doses. In animal studies. the drug was found to cause uterine contractions and
therefore the product monograph advises against its use in pregnanc y because of the possibility
of causing a miscarriage in early pregnancy or inadvertent induction of labour at term.!"
Adverse reactions with misoprosto l are primarily gastrointestinal with diarrhoea (11.4%)
abdominal pain (6.8%) and flatulence (2.9%) found.!" These side effects were found with the
full adult dose of 8oo fIlg 0.0.1.1-1 These side effects develop early in the course of treatment. are
self limiting and require discontinuation of misoprostol in only 2% of patients. In addition
pyrexia. nausea, headache and constipat ion are found 1·2 % of subjects. similar to that found in
subjects taking placebo. I""
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2.4 A cbr ee e tegy of the use ofrnisoprostol in the induction of labour
Intravaginal misoprostol has been shown to terminat e first- and second-trimester
pregnancies. The earliest studies ofmisoprostol's use in cervical ripening and labour induction
were performed by Bugalhc":" and South American investig ators,1lS. l! b, m who reponed their
experience using intravaginal misoprostot,
By 1994, 16 studies had assessed the effectiveness ofmisoprostol for cervical ripening
and labour induction . Three of these studies were uncontro lled non-comparative studies: cne'"
was an open-label dose finding study of 56 term and preterm patients requiring labour induction;
another was a review of 149 patients who underwent cervical ripening and labor induction with a
single application of 100 ug of miscprosrol:" and the third assessed the effectiveness and sa fety
of low dose (50 Ilg) intravaginal misoprostol for cervical ripening and labor induction in 666
pregnant women." Three additional studies evaluated the effectiveness of misoprostol for labor
induction in patients with fetal death: a Brazilian srudy'" reponed the use of oral misoprostol for
labor induction in 20 cases of fetal death between 19 and 4 1 weeks gestation; and two
uncontrolled srudies' ':" evaluated the use of misoprostol for termination of pregnancy in cases of
fetal dealh. A seventh study" was presented only in abstract fonn . Another study, which
compared patients who received either intravaginal misoprostol or intravenous oxytocin for
induction of labor, was not randomized and the groups had unequal allocation (404 women
received misoprost ol and 52 were induced with oxytocin).
In 1993 Sanchez- Ramos at the University of Florida performed a random ized
trial of misoprostol versus oxytocin in 130 patients undergoing induction of labour at term. He
found that the interval from induction to vaginal delivery was significantly shorter in the
misoprostol group. However, uterine tachysystole also occurred more commonly in the
16
misoprostol group although this did not achieve a statistical significance. Also in 19937J Fletcher
et al reported from Jamaica on a double blind randomized trial of 45 women who received either
vaginal misopros tol or placebo for induction ofla bour at term. In this small trial they found that
misoprostol was superior to placebo in ripen ing the cervix and inducing labour. They also found
a reduced need for oxytocin and no di fference in the two groups in delivery outcomes. neonatal
or perinata l complications.
ln 1994 Fletcher' s group reported" on a further small randomized trial of6 3 women who
received 3 mg of either intravaginal dinoprostone or misoprostol for inducing labour at term.
These studies were followed by further randomized trials by Wing et al,'!' and Varaklas et aim in
1995. Sanchez-Ramos performed a meta-analysis!" of the eight randomized clinical trials of
intravagina l misoprostol for cervical ripening· I.""'·~·7) . ' S l.I7l. ' IJ.u. and labor induction. A total of
966 patients (488 treated with misoprostol and 478 controls) were enrolled in these trial s. The
number of subjects allocated to the misoprostol group in the various trials ranged from 24 to 138,
with control groups generally of similar size (21-237). Five of the eight trials were perfonned in
the United States and the remaining three were conducted in Jamaica and Chile. The proport ion
of nulliparous patients in each group was similar (i.e. 48.7% and 46.2% for misoprostol and
control groups . respectively). All pat ients enrolled in the contro l groups received PGE! or
oxytocin. with the exception of one trial in which patients were given placebo. This meta -
analysis found vaginal misoprostol to be an effective labour induction agent. when compared to
standard induction agents. Although persuas ive. there were some problems with this stud y -
primarily those of heterogeneity of included studies and analysi s of caesarean section rates.
Firstly in these trials. there was heterogeneity in study design with respect to dosage and
schedul e of misoprostol administra tion, use of electronic fetal monitoring (EFM), end points
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evaluated, and control drug used. The dose of misoprostol varied from 25 Ilg every 2 hours to
100 ug as a single dose. The range forcumulative maximum allowable dose was from 50 ug to
600 ug. Continuous EFM and tocodynamometry were perfonned on all patients in six of eight
trials, whereas the other two used electronic monitoring on a selective basis. Oxytocin infusion
with or without selective use of PGE~ gel (0.5 mg intracervically) was used in controls in two
studies. In another, 3 mg PGE~ gel was administered intravaginally to controls. In the
remaining four studies, 0.5 mg PGE~ gel was administered intracervically in controls.
Secondly, with regard to caesarean section rates, none of the individual trials evaluating
the effectiveness of misoprostol for cervical ripening and labor induction had sufficient statistical
power to detect a significant reduction in the caesarean rate. In the meta-analysis of patients with
live fetuses who received intravaginal misoprostol for cervical ripening and labor induction, 168
of 1708 patients (9.8%) were delivered by caesarean. This is however a remarkably low rate.
compared to the American average in the same period of 20-25%. considering that many women
were high-risk and had an unfavourable cervix. Misoprostol's ability to effect changes in the
Bishop score, as well as adequate uterine activity, may have contributed to this low caesarean
rate.
All these studies showed misoprostol to be an effective labour induction agent with a
very low cost and an acceptable side effect profile. This prompted our group at Memorial
University to undertake a randomized trial"?of 222 patients who were randomized to vaginal
misoprostol or standard labour induction methods (dinoprostone and/or oxytocin). This study
found a decreased time to vaginal delivery, less time for oxytocin augmentation, a strong trend
for less use of epidural analgesia Median prostaglandin cost per patient with misoprostol was
lOOth that of the control subjects.
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2.5 Ra tionale For Studying Mtsopro stel Adm inistration In Th e Oral Form In The
Indu ction or Labo ur:
Although the standard agents used in our centre for pre-labour cervica l ripen ing and
induction of early labour (i.e.: Prepidil and Prestia) were found to be safe and effective. there were
some problems found to be associat ed with their use. They are administered every 6 hours and many
patients require severa l doses. As a result patients often had multiple pelvic examination s by
differen t caregivers and frequently spent one or two days in the pre-induction . ripening process.
Because of the relatively high costs of these formulations. this was also quite an expensive process.
These factors lead our labour and delivery unit at the Grace General Hospital in St. John's .
Newfoundland to evaluate the use of an alternative (i.e .: misoprostol) when given vaginally in a
randomized clinical trial.':" The results of this trial showed that when administered vaginally.
misoprosto l was a safe and inexpensive alternative to standard agents. Unlike vaginal prepara tions.
oral labour induction agents do not require a pelvic examination - thus reducing the number of
pelvic exams. Oral administration of prostaglandin could also theoretically reduce cborioamnio nitis
caused by repeated inoculation of the cervix by lower vaginal organisms. Finally. as misoprostol
was developed for 2ril administration. vaginal absorption has not been well studied. II is possible
that oral misoprostol to induce labour might have a more smooth and predictable dose response
curve than the vaginal misoprostol studies discussed above. We wished to evaluate whether or not
misoprosto l when administered orally, (the route for which it was marketed for its gastrointesti nal
indications), would also be an effective and safe agent when compared to standard care in the
induction of labour at term. All prostaglandins administered orally for induction of labour in
previous reports had an unacceptab le gastrointestinal side effect profile. Thus, if our study were to
demonstrate that ora l misoprostcl was a safe and effective labour induction agent. it would be the
first well tolerated oral agent described.
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CHAPTER III· METHODOI OG Y
3.t Research Questi on:
The aim of this study was to evaluate the effectiveness. safety and acceptability of a new
oral labour inducing agent (misoprostol) versus our standard regimen for labour induction. Our
standard regimen for induction of labour at term depends upon the preference of the individual
attending physician and on the state of cervical readiness. In general, if the cervix were ready for
labour, artificial rupture of membranes supplemented by titration of a dilute intravenous oxytocin
infusion is carried out. These patients would not require any prostaglandins and be ineligible to
join the study. If the cervix is not ready for labour, then pre-labour cervical ripening with the
proprietary dinoprostone agents, Prepidil and Prostin is carried out prior to amniotomy +1·
oxytocin stimulation. These patients (i.e . those requiring pre-arnniotomy prostaglandins)
represent the patients eligible for the study protocol.
We generated two groups in our proposed study. The standard group wou ld receive
usual care, including one or more of the following: I) cervical Prepidil; 2) vaginal Prostin or 3)
oxytocin. The study group would receive oral misoprostol. In order to determine a sample size,
it was necessary for us to choose a primary outcome measure. We were primarily interested in
oral misoprostol ' s ability to carry out pre-labour cervical ripening and to induce labour. Once
the patient was in established labour, we planned to manage the intrapartum care of the patient.
similarly in both groups (i.e . artificial rupture of membranes if necessary, and intravenous
oxytocin as indicated). We hypothesised, therefore, that the most important potential difference
between the two groups would be the pre-labour cervica l ripening and latent phase of the Ist
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stage oflabour. However, measurement or this phase cf the induction process is very subjective
and open to bias by unblinded observers . We thereforechose to not meas ure this as a primary , or
secondary outcome and instead measured more absol utely definable phases o r labour - for
instance length or the 2" stage etc. By choosing the length or time until delivery as our primary
outcome meas ure. we hoped to capture any difference in the latent phase. between the two
groups . Patient satisfaction surveys o f materna l satisfaction in labo ur and delivery have sho wn
that the outcome or most importance to the partu rient is length or time from inductio n or labour
to deli very (assuming a healthy outcome for both mother and baby). Although other outcome
measures such as caesarean section and operative vaginal delivery rates are clearly o r great
importance, studies to detect differences in these rates would require very large sam ple sizes. As
this was an exploratory study or a novel drug use. we felt that to conduct an initial study or this
size, with duration oflabour as the primary outcome measure was the most appropri ate course .
We were unab le to find in the literature any references on this subject . There are no published
data on the clinicall y significan t differenc e (delta) in time that either patients or caregivers
consider important when choos ing an induction agent. We therefore chose to poll opinions of
memberso f the medical and nursing staff in the labour and delivery unit at our centre. It was the
consensus from these discuss ions that a difference of four hours (240 min.) between our two
groups wo uld be clinical ly important. In retrospec t, we regre t that we did not poll patients prior
to the study regardi ng their perspective on the delt a, although we did study this with our post
care questionnai re. As experience grows with this method of induction. the clinically signi ficant
delta asestimated by the patient should be considered in future studies.
Our primary research question therefore becam e ""wbeg ttllOpared with our eurreat
stao dard jgduction p ro tocol does oral administration of misop rostol for labour iod uedo a
2\
differ by mor e than fOUf hours in lime to vagin al birth ?" It was our hypothesis before the
study that women prefer to have a labour induction agent administered orally by being handed a
tablet to swallow by a nurse rather than by vaginal insertion of a gel by a member of the medical
staff. Because we felt that the differences between the two groups would be found in the pre-
induction cervical ripening phase of the induction process (without the pain of the active phase of
labour). we felt that many women might be prepared to spend an extra four hours in the pre-
labour ripening process in order to have their medication administered orally rather than
vaginally.
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3.2 Outcome Measures:
Our outcome measures were both primary and secondary. As described in section 3.1,
our primary outcome measure was the length of time from commencing the induction of labour
process until vaginal birth of the neonate. The clinically significant difference chosen as
important was four hours (240 mln.). This primary outcome specifically addresses the issue of
effectiveness but we also wished to prospectively evaluate issues of safety and patient
acceptability.
With regard to maternaloutcomes. we recorded the following:
i ) Number of doses of prostaglandins.
ii) Prostaglandinside-effects.
iii) Durationof the three stages of labour.
iv) Route of delivery.
v ) Operative interventions. and their indications.
vi) Use of narcotic and epidural analgesia.
vii) Oxytocin augmentation and its duration.
viii) Blood loss and blood transfusion.
ix) Perineal trauma.
xl Post-partum pyrexia.
xi) Length ofstay in hospital.
Risks to the fetus from the use of prostaglandins for the induction of labour consist of
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uterine hyperstimu lation causing excessive contractions of the uterus with subsequent diminished
placental perfusion and umbilical cord flow resulting in possible hypoxic consequences for the
fetus. These fetal effects might be suggested by the development of non-reassuring fetal heart
rate tracings and/or meconium liquor." Appropriate responses to these findings would be either
fetal scalp arterial blood gas sampling or operative delivery for non-reassuring fetal heart rate
changes.' Data regarding these interventions was prospectively gathered. Immediate postnatal
outcomes measures were chosen based on the recent policy statement by the American College
of Obstetricians and Gynaecologists concerning the diagnosis of perinatal asphyxia. ' .•
Accordingly in addition to Apgar scores (an assessment of fetal health at I and 5 minutes of life),
we also carried out umbilical cord arterial blood gas sampling and physical exam for signs of
neurologic abnonnality and multi-system organ failure on all neonates. As this is currently not a
standard of practice at our centre (or in most centres in Canada), all neonates in our study were
subjected to a more rigorous evaluation than those outside the study. We also recorded neonatal
hypoglycaemia which could represent a long and difficult labour. any neonata l pyrexia. number
of days in the neonatal intensive care unit and number of days in hospital.
Maternal Satisfact ion:
In recent years there has been increased interest91.9~J IN. 1I "' 1l 7.l }.O.I~l . IlW.I1~ in maternal
satisfaction with the labour and delivery process. We felt that materna l satisfaction was second
only to safety in importance as a secondary outcome measure. Our a p rio re assumption was that
the patients who had induction of labour by oral misoprostol would have a more acceptable fonn
of induction. as they did not have a vaginal administration or intravenous administratio n of
medication. However. we wished to prospectively evaluate this issue. We were also interested
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in the mothers satisfaction with all aspects of her labour, not simply her preferred route of
administration of the induction agent.
Accordingly, we asked all entrants in the trial to complete a maternal satisfaction
questionnaire (Appendix V). This questionnaire was a modified Labour and Delivery
Satisfaction Index (LADSI).I'. This LADSl scale is a validated quality of life tool, one of a
number developed in the 1980's . It's use has fallen over the past 5 years, due to the high use of
E. Hodnett's labour agentry scale."
The questionnaire contains 38 questions concerning various aspects of the birth process.
We added an additional four questions to the original LADSl score, specific to this trial. but
scored in the same fashion. These additional questions were considered to be exploratory and
were nm pretested. Clearly, therefore any inferences based on these additional questions need to
be viewed with caution. The total LADSI scores for the standard LADSI questionnaire were
calculated bWIl: consideration of these extra questions. Therefore the additional questions were
felt not to affect the interpretation of the standard LADSI score.
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3.3 Desigo :
This question requires a random ized control trial. One group o f patients would receive
our study intervention (oral miso prostol). The second group, (the stand ard group), would receive
the usual protoco l for induct ion of labour at our cen tre. In order to bl ind obstetric al caregivers,
it wo uld have been necessary to insert a placebo gel intravagin ally in those patien ts who were
recei ving oral misopro stcl and we did not feel that this was justified. As many of our seco ndary
outcome measure s were neonatal , we did however, blind neonatal careg ivers as to wh ich
induc tion protocol the neonat es mother had received.
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3.4 Subject Speclficatioo:
The subjects whom we felt were eligible for our study were all those patients admitted to
labour and delivery unit of the Grace General Hospital in St. John's for induction of labour at
term. Exclusion criteria were as follows:
I ) contra-indication to vaginal delivery-
2) non-vertex presentation
3) non-reassuring fetal heart rate tracing
4) prior uterine surgery
5) documented hypersensitivity to rnisoprostol or other prostaglandins
6) history of asthma (which can be exacerbated by prostaglandins ).
[n order to maximize external validity we did not exclude patients who had other obstetrica l
problems such as pre-eclampsia. known intrauterine growth restriction. known oligohydramnios.
or insulin dependent diabetes. Although we recognize that these obstetrical complications could
carry an increased risk of sub-opt imal outcomes (for instance. caesarean section), randomization
alone would minimize any confounding bias.
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3.5 Description or Experimental Manoeuvre :
The experimental manoeuvre in this trial was the administration of oral misoprostcl for
the induction of labour. As there were no reports of the oral administration of misoprostol for
induction of labour in the literature. we had to generate a dosing protocol for the administration
of oral misoprostol in our labour and delivery suite. In doing so. we were guided by two main
considerations: I) with regard to its use in the prevention of our gastrointestinal ulceration. the
recommended '.... dosaging is in 100 - 200 microgram tablets up to a maximum of 800
micrograms! day; 2) when administered vaginally both in our centre and in other centres. the
most commonly administered dose was that of SO micrograms per vagina every four hoors.!"
Our concern was that oral misoprostol might not be as effective an agent as vaginal misoprosrol.
Therefore. we were concerned that patients receiving 50 micrograms of oral misoprcs tc l every
four hours might encounter minimal or no response to this dosage. Accordingly. as pan of our
oral misoprcstc l dosage protocol. we allowed an increase of the dose of misoprosto l to 100
micrograms orally every four hours following two 50 microgram doses without the desired
response. This increase was at the discretion of the attending physician in the event thai there
was minimal or no clinical response to treatment with 50 micrograms every four hours, as judged
by the patient's symptoms and cervical examination. This dose was not to be exceeded.
All study inductions were carried out on an in-patient basis and all patients randomized 10
receive oral misoprostol were cared for continuously in the labour and delivery suite from
randomization until delivery. Continuous electronic fetal heart rate monitoring was carried out
for two hours after administration of all prostaglandins and during established labour.
The experimental manoeuvre therefore, was to create two groups of patients. The study
group would receive miscprostol 50 micrograms orally every four hours as a minimum dose up
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to a maxi mum dose of oral misopros tol 100 micrograms every four hOUTS. The standard group
would receive usual care which in our centre consists of Prepidil 0.5 milligramsintraccrvically
every six hours or dinoprostone 1-2 milligrams intravaginall y every six hours or a dilute solution
of oxytoc in administered intravenously. The choice of the agent to be usedin the standard group
rested with the individual attend ing physician caring for that patient based on whichever option
the physician felt was opt imal for the care of that partic ular patient.
In both study and control groups . prostagland ins were combined until the patient was
contracting regularly and had a Bishop score which allowed artificial rupture of membranes .
Once rupture of membrane s was carried out. oxytocin augmentation was commence d.
subsequently. if there were inadequate cervic al change. The decisio ns with regard to timing of
membrane rupture and oxytocin augmentat ion were made by the an ending staff. with no
maximum or minimum number of doses of prostaglandin set. Again. as this was an exploratory
study, we did not mandate criteria for commenci ng oxytocin as we felt it safest to allow the
attend ing staff to judge whether or not it was indicated, bearing in mind the many variables
present - patients pain. fetal heart rate tracing. ere.
Two possible criticisms of the study design arise at this point . Firstly. heterogeneity in
the standard arm could cause diffic ulry in comparing the two groups . Secondly, the protocol is
liberal in the initiation and timing of the two major co-interventions - artificial rupture of
membranes and commenc ement of oxytocin.
Our purpose however was to design a "real life" trial where our new intervention - oral
misoprosto l • was compared to the best care that could be given to the standard group. In the
routine day to day care of non-study patients. practitioners choose the best agent from the
heterogenous armamen tarium available. which can be tailored to the patients needs. By mirroring
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this practice in the standard arm of the trial, we hoped to provide as "strong" a comparison group
as possible to our study drug. Thus. patients in the standard arm were not denied the best
possible agent for them - complying both with the "first do no harm" ethic and providing the
optimal yardstick by which to measure the new agent.
Similarly, we allowed artificial rupture of membranes and/or oxytocin usage when the
attending staff felt it optimal for anyone patient' s care.
Viewed in this way, we felt that the heterogeneity and freedom of timing in the study
design were strengths rather than weaknesses. as two groups could be assembled and compared -
i.e. best possible obstetric care using standard induction agents versus best obstetric care using
oral misoprostol. As this was a non-blinded study, the risk of bias docs arise, when interpreting
the results of the study, however we felt that a direct 2 group comparison k2.llkI be made.
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3.6 J usti fica tio n of Sample Size:
As alluded to in section 3.1, we chos e asour primary outcome measure the length of
time from commencement of induction of labour until vaginal birth, with clinically significant
time difference between the two groups o f four hours. or 240 minute s. In order to calculate a
samp le size , we also needed a mean and standard de viation from the time of induction of labour
to vaginal birth at our centre . We obta ined these figures from the previous trial l ~l carried out on
vaginal misoprostol at our institution . The mean of time from induction o f labour to del ivery
was 94 1 minutes and the stan dard deviation 550 minut es. With regard to type I and type II
errors we chose a two-tai led a. of 0.05 and a I.~ of95 . Th is is a smalle r type II error than the ~
o f 0.20 usua lly chosen in simi lar trials . We chose a smaller than usual type II error in order to
reduce the chance of missing a true differe nce betwee n the two groups .
If such a differenc e were missed . the risk would be that this new technique might be
incorrectly offe red to the large population of induction patients and man y women could
subsequently suffer long er labours as a consequence. Samp le size for our study was calcu lated
by the follow ing calculation: 101
Sa m ple size ca 1c:" latioQ
Sample size for t-test comparison of 2 means II is as follows :
N
2N
2N
2N
2(~
A'
4~
If a. 0.05. (two sided) , then l.,=L96,
~ 0.05, then Z~= 1.645,
tJ. 240 ,
a = 550 (standard deviation fromprevio us study).
4f1 96 + I 645)~ 550"
240'
273
Therefore the sam ple size for the study was 273 subjects.
3\
As earlier experience with misoprostcl studies in our centre had found a zero "drop out"
rate, we chose not to increase the sample size to allow for dropouts. This decision was justified
by the zero drop out rate found in this study.
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3.7 Description of Institution Where Stud y Performed:
This study was performed in the labour and delivery suite of the Salvation Army Grace
General Hospital. St. John's Newfoundland between February 28. t995 and September 10. 1995.
This centre is the provincial perinatal unit with a regional perinatal mortality rare of less than
10/1000 and a maternal mortality rate of < 10/100.000. The Grace Hospital is the provincial
referral centre for complicated pregnancies and offers a tertiary level neonatal intensive care unit.
Annually. there are about 7.000 birthsiyear in the province with approximately 2800 at our
centre. Our facility offers a full epidural service and is a teaching hospital with undergraduate
medical and nursing students in addition to post-graduate residents in obstetrics and
gynaecology. The patient population is predominantly (>95%) Caucasian of European ethnic
origin. During the day care is provided by the attending physician. and at night time an "on-
call" obstetrician remains in the facility continuously until care is reassumed by the patient's
attending physician the following morning. The caesarean section rate for women undergoing
induction of labour in our centre averages 15%. Overall caesarean section rate is approximately
18 - 20%. commensurate with similar centres across Canada.
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3.8 Ethics and Consent:
This research proposal received the approval of the Human Investigation Committee of
the Salvation Army Grace General Hospital, St. John' s and the of the Faculty of Medicine,
Memorial University, Newfoundland.
All potential subjects were counselled fully by an obstetrics resident and/or attending
obstetrician prior to signing the consent form (see appendix II). All patients were given a patient
information sheet, to keep. These efforts supported informed choice.
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3.9 Patient Recruitment:
Candidates for the study were initially approached regarding enrollment at one of three
different venues. The first venue would be in the offices of the attending physician when the
decision was made to schedule the patient for induction of labour. At this time, the attending
physician would explain the study to the patient and explore the risks and benefits of enrolling.
The second venue: was at OUI Fetal Assessment Unit. where the majority of patients whose
pregnancies of 41 weeks or longer are seen for an ultrasound evaluation of fetal health, known as
the biophysical profile. Since many patients are scheduled for induction of labour following this
biophysical profile, they were approached and counselled at this time regarding enrollment in the
study. Any patients who expressed an interest were given an information sheet (see appendix X)
in order to consider the issue further before they came through the labour and delivery suite for
the induction process. The third venue where patients were approached was the labour and
delivery suite. Patients were occasionally seen for induction of labour without having been
evaluated in the Fetal Assessment Unit or having had the trial discussed with them by their
attending physician. At this point, the initial offer for information regarding the study to the
patient was made by the nursing staff with subsequent counselling by the resident or attending
medicalstalT.
Regardless of venue of initial counselling. all patients were seen again in the labour and
delivery suite. They then had a repeat, detailed counselling discussion with either an obstetrical
resident or an attending physician regarding all the risks and benefits implicit in enrolling in the
trial. both in the study and in control groups. Patients were then given time to consider the
issues and discuss it privately with their partners. The counsellor reattended to answer any
further questions present before the consent fonn was signed. The voluntary nature of
3S
enrollment in. and continuation within the trial were underlined to the patient both in the consent
fonn and verbally. No effort was made to coerce patients to enter the trial and any patient who
expressed any misgivings about enrollment was not enrolled. It was made as clear as possible to
trial candidates that a decision not to enroll would in no way negatively impact on care.
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3.10 Randomization Process:
Randomization was achieved with the use of random number tables blocked in fours.
generated by a computer program. Numbered cards were then marked either "Oral Misoprostcl''
or "Standard" and placed in numbered opaque envelopes. by an administrative assistant not
involved in patient care. Randomization was carried out within two different strata;
I) patients with intact membranes at induction of labour.
2) patients whose membranes had spontaneously ruptured prior to enrolling in the trial.
Two sets of sequentially numbered envelopes were left in the labour and delivery suite.
When an eligible patient had been seen and counselled fully and signed her consent to
enroll in the trial, a pelvic examination was carried out in order to provide a blinded baseline
assessment of cervical ripeness. This ripeness is evaluated as a Bishops Score (table I) and
represents as objective an assessment of cervical preparedness as possible. Following this
evaluation. the next envelope in sequence was opened and group assignation made. Once the
envelope had been opened, the patient's name was written beside the number of the envelope and
on the sheet of paper accompanying the envelopes. This list of recruited patients and their
corresponding open envelope was checked twice daily by the principal investigator. By strict
adherence to this process. we were able to ensure that no envelopes were opened out of sequence.
that no envelopes were lost and that no envelopes were skipped. Meticulous care was paid to this
entire process since in the past. criticism!" has been levelled at the "sealed envelope" fonn of
randomization. as being prone to caregiver interference and randomization bias.
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J .I I Data Handling:
Data were recorded on the sheets shown in appendices III and V. This process was
carried out in two stages, firstly, prior to leaving the hospital, the patient W:J.S given me lADSI
questionnaire desc ribed in section 3.2 and asked to complete and return the same . She was also
given the opportunity to comment on her care with the investigator. Subsequently primary and
secondary outcome data were abstracted from the maternal and neonatal charts . The raw data
were then transferred to a computer database . At no time did the principal investigator have
access to the pooled data, Subsequent data storage and analysis was carried out with the aid of
the "S tatistix" 4.1 computer software package (Analytical Software. Tallahassee . Flcridal .
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CH APTER IV '
Data were analysed on an " intent to treat" basis by parametric (Student 's t) and non
parametric (chi-square. Fisher exact, Mann-Whitney U) statistics as appropriate , using "S tatistix
4.1" (Analytica l Software . Tallahassee, Florida). The primary outcome measure was cons idered
significant if P< 0.05 (as per sample size calculation). In view of multiple significance testing,
other analyses were be considered exploratory and significant only if P< 0.00 1, a conservative
approach .
Results:
None of275 randomized subjec ts withdrew or were lost to follow up.
4.1 Demog rap hic:Analysis
Maternal pre-induction and neonatal demograph ic data are presented in Table I. As
would be expected from randomization, no statistically significant differences were seen betwee n
the two groups. However, there are 2 apparent imbalances which occurred by random chance .
Firstly, "oligohydramnios" was the induction indication in 9 standard patients, but only 1 study
patient . Because oligohydramnios may result in an increased incidence of non-reassurin g fetal
heart rate tracing, this imbalance~ have slightly increased the risk of caesarean sectio n in
"standard" group patients . This possibility would have been otTset by the other imbalance which
arose by random chance -- there were 16 more patients with a poor Bishop Score «6) in the
study group , than in the standard group. Neither of these demographic parameters were
statistically significant differen t between the 2 groups and are not indicative of failure in the
randomizatio n process.
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TA RI F I Demog raphjc Data
Misoprostol Control
N= lJ7 N=1J8
Pre-in duction
Nulliparous 86 94
Induction Indications
Post term 81 74
PROM 26 30
Hypertension 8 14
Oligohydramnios 1 9
Other 21 11
MaternalAge in years 27.3 15.11 26.8 (4.61
Gestation in days 282.9 (10. 11 284.2 (8.6)
Gravidity 1.8 (1.0) 1.6(0 .9)
Parity 0.5 (0.7) 0.4 (0.7)
Bishopscore median 5 (3.7) 6 (4 .7)
Bishopscore < 6 82 64
Neonatal 3581 (528) 3539(485)
Birthweightin grams
Datagiven as number, mean(standard deviationSO) ormedian Imterquartile range) as appropriate.
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4.2 Pr ima ry Outcome Measure: T ime fr om commencin g induction until delivery.
Data for mean vaginal birth intervals are presented in Table U. No statistically significant
differenc e between the two groups was found in the primary outcom e measure . Mean time from
induction to vaginal birth in the study group was 926 minutes. and in the standard group was 909
minut es. a differe nce of only 17 minutes (PO.8 I) .
An analysis of the primary outcome with non-parametric sta tistics . allows inclusion of
birth interval data from caesarean patien ts. A caesarean birth is a failure to de live r vaginall y
(time to vaginal birth is infinite>. and therefo re is ranked longer than any vaginal birth. Rank
order methodo logy makes no assump tion regarding normal distribut ion. is statis ticall y
conservative . and uses median s as the measure o f centra l tendency. By employing this analysis.
the two groups cou ld be compared without exclud ing caesarean sections from the data. The
medi an time to vagina l birth was 882 minutes for contro l subjects and 958 minutes with ora l
misopros tol (P:O.16. Mann-Whimey V). Again no statisticall y significant difference was found
between the two groups .
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TA BI E n Pri m.ry Outco me ~ICJ$g[e
Misoprostol Control P
N=116 N= l2S
Induction to binh 926 (521) 909 (585) 0.81
Data given In mmutes as mean (SO)
P by Student' s I test.
42
4.3 Secondary Outcome M~uurn:
4.3.1 Labour I nt~rvab:
There were no significant differences between the two groups in the other relevant
peripartum intervals when analysed overall. irrespective of membrane status. table m.
Analysis was also carried out according to stratification by membrane status . In
participants who were stratified as membranes ruptured. the interval 10 vaginal birth was a mean
of 734±468 minutes with oral miscprostcl versus 557±3t2 minutes (P=O.13). Durations of
membrane rupture were 2149±908 minutes and 19S2±6S1 minutes (P=O.l l). In subjects who
were stratified as membranes intact. the interval to vaginal birth was a mean of 974±524 minutes
with oral miscprostot versus IOO2±606minutes (P=O.73). Duration of ruptured membrane status
were 296±278 minutes and 330±266 minutes (P=O.40). Again. there were no statistically
significant differences in delivery times between the groups when analysed according to
membrane status strati fication.
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TABl E III l abour InteO'als Unstratifie d
Miscprostel Control P
N~ 1l6 N=125
Induction [0 full dilation 859 (487) 844 (549) 0 .83
Membranerupture duration 664 (877) 667 (76 1) 0.9 7
Firststage 348 (247) 352 (2 18) 0.89
Second stage 63 (68) 75 (79) 0.22
Third stage 10 (10) 11 (9 ) 0.86
Datagiven m mmutes as mean(SD)
P by Student's t test.
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JABI E IV I abour Inte rvals
A "'Ruptured Memb ran es"
O ral Mlsoprostol Con trol P
Induc tion to Vaginal Birth 734(468) 557(312) 0.13
Duration of Membrane Rupture 2149(908) 1952(65 1) 0.11
Data expressed mmmutesas meanand standard deviation
P by students t test
B "'Intact Membranes"
Oral Misoprostol Contro l P
Inductio n to Vaginal Birth 974(524) 1002(60 6) 0.73
Dur ation of Membrane Rupture 296(278) 330(266) 0.40
Data expressed in mmutes as mean and standard deviation
P by studen ts t test
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4.3.2 Birth route :
There was no difference in birth route (table V), (chi-square "" 3.51. three degrees of
freedom, P=O.18). With oral misoprostol there were 93 spontaneous deliveries, 13 vacuum. ten
forceps assisted. and 2\ caesarean births. With control protocol, there were 103 spontaneous,
nine vacuum, 13 forceps assisted and 13 caesarean births. There was no statistically significant
difference in caesarean births [relative risk (RR)=1.63. 95% confidence interval (CI)= 0.85 to
3.\ 2] between the two groups. However, the fact that there were 61% more caesarean sections in
the misoprostol group, than in the control group deserves further assessment of its d.in.i£LI
significance. This issue is addressed in the discussion, Chapter 4. Non-reassuring fetal status
was the indication for nine caesareans with oral misoprostol and six control participants
(RR= 1.51, C[= 0.55 to 4.13). In subjects who were stratified as membranes ruptured, three
caesareans were done in the study group and four in the control group (RR=0.87, CI=0.21 to
3.52). With membranes intact, there were 18 caesareans with misoprostol versus nine with
control protocol (RR=L 95, Cl=0.9 1 to 4.14). The numbers involved in this sub-analysis post
stratification are too small to allow inferences to be made.
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TARt E v RirthRoute
Misoprostol Control Relative Risk Ceefldenee loterval
N = 137 N "" 138 5% 95%
Spontaneousdelivery 93 103 0.9 0.62 2.2
Vacuum delivery 13 9 1.44 .82 3.2
Forceps Delivery 10 13 0.76 0.6 2.1
Caesarean Section 20 13 1.63 .85 3.12
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4.3.3 Materuallncerventi ons:
Table VI summarizes the data concerning peripartum maternal interventions. There was a
difference in oxytocin use, but this was undoubtedly influenced by the fact that vaginal PGs were
conside red contraindicated with membranes ruptured. Use of oxytocin was less (RR:::0.38 .
Cl :::Q.24 to 0.63) with oral misoprosto l induction when membranes were ruptured. but not with
intact mem branes (RR:::Q.78. Cl:::Q.5S to 1.10).
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TAB I E VI Matema l l nteryentioQ withQut stratilicatio n
Misoprostol Control Relative ConfidenceInterval
N=137 N=138 Risk
Intrapartum Frequency S% 9S%
Oxytocin used
46 7S 0.62 0.47 0.82
Epidural 68 74 0.93 0.74 1.16
Noanalgesia IS IS 1.01 0.51 1.98
Meconium 20 2S 0.81 0.47 1.38
Scalp pHdone 4 S 0.81 0 .22 2.94
NRT" 22 13 1.70 0.90 3.24
" Non-reassuringfetal heartratetracing.
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4.3.4 Maternal Outcome s:
Oral misoprostol use was not associated with increased perineal trauma. table VII. No
subject in either group received pharmacologic or caesarean intervention for uterine
hyperstimulation. Manual removal of the placenta after vaginal birth was carried out on two
patients in each group. A single oral misoprostol recipient was given a blood transfusion
subsequent to a caesarean incision extension into the broad ligament. With regard to
gastrointestinal symptoms, emesis was reported in four participants in the control group and one
with oral misoprostol (P=O.37. Fisher exact test). No patient in either group developed diarrhoea.
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TA BI E VI l Maternal O utcomes
Misoprostol Control Relative Confidence Interval
N= 137 N= 138 Risk 5% 95%
Episiotomy 34 40 0.86 0.58 1.27
lac eration 59 75 0.85 0.67 1.09
Third I fourth degree 3 5 0.60 0.15 2.48
l aceration
Intact perineum 29 23 1.27 0 .78 2.08
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4.3.5 Neonatal Out comes:
Neonatal outcomes were similar (Table VUD. Umbilical cord blood acid base analysis
was performed in 216 participants (78%). There was no difference in mean cord blood pH. mean
base deficit or median 5 minute Apgar score between the two groups. The frequency of cord
blood pH less than 7.15 (t I in study group versus seven in control) was nor different (RR""1.49,
Cl= 0.60 to 3.69). One neonate in either group had 5 minute Apgar score less than seven. No
neonate developed respiratory distress syndrome or meconium aspiration.
While there was no mother whose neonate met the ACOG criteria for birth asphyxia, one
control group neonate did develop neonatal seizures. This mother was an insulin dependent
diabetic whose labor was induced at 38 weeks gestation with vaginal dinoprostone . When a non-
reassuring FHR tracing developed. preparations were made for a caesarean, but the cervix
became fully dilated and a vacuum assisted delivery was performed. This infant had Apgar
scores of 4 at I minute, and 9 at 5 minutes. a cord artery pH of6.90 and a base deficit of 19. The
neonate developed seizures requiring therapy and at 9 months postnatal follow up has moderate
developmental delay.
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TAR' E VlII Neo natal Outcom es
Misoprostol Control P
N~ 137 N= 138
Median Quartile Median Quartile
Apgar 1 min 9 (8.9) 9 (9.10) 0 .87
Apgar5 min 9 (9. 10) 9 (9. 10) 0.54
N N
Apgar I min < 7 21 15 0.27
Apgar5 min < 7* 1 1 1.00
Mean SD Mean SD
Cord pH 7.28 (0. 10) 7 .28 (0. 10) 0.86
Basedeficit 4 .9 13.5) 5.2 13.8) 0.38
ACOG Criteria fer
N N
Apgar5 min 3 0 0
Cord pH < 7.00 3 2 1.00
Base deficit > 16 2 3 0.68
Quartiles are2S and75 percent.
Cord blood acidbasedataarefromIII and105neonates respectively.
P formedianby Mann-whitney U, andformeanby Student's t test.
P forcategorical databy chi-square,except as • indicatedby Fisherexact test.
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4.3.6 Post-partum Outcomes/C osts: (tables IX a and b)
There were no differences between the 2 groups with respect to the number of days in
hospital for mother or baby. The only difference in health care costs between the 2 groups,
therefore. is~ cost. As misoprostol's cost per dose is 0.01 that of dinoprostcne,':" the
difference potentially does have significant cost saving implications if its use becomes
widespread.
There were no differences in maternal or neonatal fever rates between the 2 groups.
Crude measures of neonatal well-being post delivery, (hypothermia and hypoglycaemia ) were
also equal in both groups.
Of interest. is that the mean number of pelvic exams was the same in the study and
standard groups. This higher than expected number of pelvic exams in the oral misoprostol group
may have been caused by caregivers unfamiliarity with this new induction protocol. (ie frequent
pelvic exams prior to decision regarding the number of doses of oral misoprostol).
S4
Ta ble IX . Post ~ partum Outcom es/Costs
A Maternal Oral misoprostol Standard P
Hospitalization
(mean # days) 3.9 4 .1 NS
meannumber of Days
temp. >38.5°C 0 0 NS
Total number vaginal
examinations (mean) 5 5 NS
B Neonatal Oral misoprostol Standard P
Hospitalization
(mean # of days) 4.0 4.1 NS
meannumber of days
temp. >38°C 0 0 NS
mean # days
temp<36.5°C 0 0 0
Dex.trostick <5MMol 75 75 NS
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4.3.7 Prostaglandin Dosages:
Oral misoprostol was used a median of three doses and maximum of eight doses. Fifty-
nine study group subjects received a 100 ug oral misoprostol dose at least once. with a median
two. and maximum six doses. In the control group 94 patients received dinoprostone. II
received vaginal misoprostol and 33 received intravenous oxytocin only. The maximum number
of vaginal PG doses was six with a median of two. Induction interval, birth route, and neonatal
outcomes for participants who received vaginal misoprostol in the control group were not
different from other subjects in their assigned group.
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4.4 Maternal Satisfaction Results:
Of the 275 patients in the study, 189 questionnaires were returned for analysis. This
response rate (70%) is typical of questionnaires of this kind. and is sufficient to allow analysis.
Of the 189 respondents; 5 patients were excluded. as 4 or more questions had not been answered
(by convention questionnaires with 10% or more unfinished questions are not included in the
analysis) . In a further 5 patients. 3 or less questions were unanswered. In these patients; as per
convention," the mean score for that patient's questionnaire was substituted for any unanswered
question.
All questionnair es were then reviewed and cumulative score obtained. This tota l score
represents the overall measure of satisfaction with the birth process. For positive statements. the
maximum score is to. For negative statements. the score is inverted. so that a patient who totally
disagreed (score I) with a negative statement had a score of 10 ascribed for that statement. The
most satisfied a patient could be with the study therefore is a total score of 380 (38 statements. 10
marks per statements).
Table Xa contains the total scores and means from all returned questionnaires. There was
no statistically significant difference between the total score means in the two groups,
demonstrating comparabl e satisfaction with the labor process group regardless of the method of
induction.
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TA BI E X a To ta l . ADS I Sco res Fro m Satisfaction Q uest jooajres
Standard
Group # Patients Total Mean Variance Deviatio
n
Standa rd 85 28143 331.1 3281.2 57.3
Misoprostol 99 34326 346.7 1212.9 34.8
Difference -15.6 NS
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4,4 B Additional Study LADSI Questions
Table Xb displays the perceived incidence of gastrointestinal side effects between the 2
groups.
x..h M eaD Sco res (or addj tio na l q ues ljo ns
Standard Study Significance
Question # 39 7.3 8.3 NS
Question # 40 5.1 6.4 NS
Question # 41 7.3 8.6 NS
The answers to 39 and 40 indicate that there were no differences in the perce ived incidences of
gastro intestinal side effects between the two group s. This is the first docum entation of the use
of an oral prostaglandin to induce labour which is well tolerated.
However the following points should be noted : firstly, this is a relatively small study,
with only 137 patient s receiving oral misoprostol. Secondly, this part of the quest ionnaire was
not pre-tested or validated . Thirdly, a dichotomou s choice - regarding presence or absence of
gastrointest inal symptoms may diminish the reporting of minor GI symptoms. A graded set of
symptoms choices should be provided in future studies.
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4.4 C : Choice of Dr ug Route
Question : I would prefer oral rather than vaginal administration (Agree 10 - Disagree 1).
Table Xc demonstra tes patients preferences with regard to route of induction agent
respondents clear ly prefer induction by an oral agent in both groups.
Xl: C bo jceo' Drug Route
Q41 Standard Study To tal
1 6 4 10
5 3 3 6
6 4 0 4
7 0 1 1
8 2 1 3
9 3 4 7
10 16 29 45
Total 34 42 76
In both groups, patients would clear ly rank oral over vaginal drug administrati on. This
question leads in to question 42. regarding the extra number of hours that patients would be
prepared to spend in the induction process, in order to receive an oral rather than 2 vaginal doses .
When asked (question 42) : how many extra hours would they be prepared to spend in the
induction process . in order to have oral treatment all patients responded "zero" . Although this
question was worded carefully in order to underline that TOTAL induction to delivery time was
the issue. it is possib le that some patients felt that the question concemerlllilin.fi,l1labor lime. If
this were the case , it may partiall y explain the unanimi ty among patients that they would not
wish to spend any extra time in the induction process.
60
Had the choice been presented on a continuous scale, it is possible that some, if not most,
patients would have indicated I or 2 hours of induction time as a reasonable "price" to pay for
oral drug administration. This question. therefore. was not well designed in the study and the
issue remains open. to beelucidated by further research.
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CHAPTER V · DISCUSSION AND CONClI ISIO NS •
5.1 Discussion:
Since the report of Sanchez-Ramos et al in 1993, I I I there has been increasing interest in
vaginal misoprostol as a method for labor induction, probably because it is so inexpensive. His
RCT has been followed by several others (including the one from our centre) all of which have
supported vaginal misoprostol as cost effective. No investigator has found a significant increase
in substantive adverse neonatal outcomes, although an increase in uterine tachysystole has been
observed.!" Pharmacokinetic data on low dose vaginal misoprostol use at term are lacking.'''''
As discussed in the rationale behind this trial. there are no other reports using oral
misoprostol for term labor induction with living fetuses. However after completion of this Erial,
but before its publication. Ngai et al'" in Hong Kong reported a double blind ReT with a single
200 f.lg oral misoprostol dose versus placebo for cervical priming. in pre-labor rupture of
membranes at term. Twelve hours later an intravenous oxytocin induction protocol was begun. if
the participant was not in progressive labor. Thirty-nine subjects received oral misoprostol, with
41 receiving placebo. The Bishop score was significantly improved with misoprostot (P<O.05).
Thirty- four women given misoprostol went into labor without oxytocin. compared to 20 of those
given placebo (P<O.OO I). Interval to onset of uterine activity and delivery were both shorter with
misoprostol (P<O.OI). There were three caesareans in each group. Neonatal outcomes and
gastrointestinal tolerance were comparable. The authors concluded that a single 200 ug
misoprostol oral dose was effective for cervical priming, and may be effective for labor
induction.
The oral misoprostol protocol and its purpose in our study are different from that of the
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Hong Kong investigators. Our median cumulative dose per subject for labor is similar to their
single dose. It is reassuring that they did not find a significant problem with excessive uterine
activity.
The Hong Kong study of oral misoprostol for pre-induction of labour and the study
reported in this thesis along with the trials previously discussed in section 1.6 contribute to an
evolving body of evidence that misoprostol is an effective agent in the induction of labour at
term in human pregnancy.
As both oral misoprostol and standard methods were equally effective. this was a
negative trial. where the only difference found between the groups was in the use of oxytocin -
less oxytocin was used in the PROM patients who were randomised to oral misoprostot than
standard methods. This difference is explained by the fact that vaginal prostaglandins were not
offered to PROM patients in our centre at the time of this trial - thus skewing the numbers in
favour of the oral misoprostol group. However. the most important consideration in the
assessment of any new intervention is~. Before oral miscprostcl can be adopted for
widespread use, its safety for both the fetus/neonate and mother must be demonstrated. Because
no neonate in our study was assessed an Apgar score at 5 minutes of 3 or less. none met the
ACOG criteria for birth asphyxia. The new-born of most concern was described previouety.t-"
and was born to a control group participant induced with vaginal dinoprostone. The frequencies
of other commonly reported worrisome neonatal short term outcomes (Apgar score at 5 minutes
of 6 or less, and cord blood pH less than 7.15), or other indicators of possible compromise of
intrapartum fetal well-being, (non-reassuring FHR monitoring, frequency of fetal scalp pH
sampling. and meconium stained amniotic fluid) were not increased. There were also no
differences in length of stay in hospital or neonatal pyrexia etc. while in hospital. However. it
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must be pointed out that neonatal asphyxia is an uncommon event and that this study was not
designed with the power to demonstrate a difference in neonatal asphyxia between the 2 groups.
Such a study would require a larger sample size than the 237 cases reported in this thesis.
The second major consideration with regard to safety is that of the mother 's safety.
Again, no statistically significant difference was found in perineal trauma, peripartum
intervention. or routes of delivery. The most significant risk of any induction agent. uterine
hyperstimulation, is shared by both neonate and mother. If uterine hyperstimulation with
concern for fetal status subsequent to oral misoprostol occurred, operative delivery or
intravenous tocolytic therapy with an agent such as ritodrine would be necessary. Lavage or
removal of tablet remnant, an option in vaginal PG use. is not possible. No subject in either
group was treated with tocolytic agents or caesarean for uterine hypersumulation.
One of the most important and interesting aspects of this trial is the issue of caesarean
section rates in the two groups while the frequencies of caesarean birth overall (RR=t.63 .
CI=O.85 to 3.12) or for non-reassuring fetal status (RR=I.5I, CI=O.55 to 4.13), were not
different. the difference in the caesarean section rates in the 2 groups (67% higher in the oral
misoprostol group) is of great interest to the clinician. This trend towards a nigher caesarean
section rate in the oral misoprostol group is particularly strong in the intact membranes stratum.
and almost achieves statistical significance. In fact. a further 5 caesarean sections in the oral
misoprostol group would have caused a statistically significant difference.
The trend towards such an important outcome as an increased caesarean rate with oral
misoprostol' s use is disturbing, particularly in light of the~ caesarean section rates seen with
its vaginal use. when compared to standard methods. Clearly. if its use~ increase the risk of
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caesarean section, oral misoprostol could not be considered for routine use in labour induction.
When consid ering this issue, however, the following should be considered: firstly, a statis tically
signific ant difference was nQ1 found between the two groups . Second ly, the caesarean section
rate was a secondary outcome - one of 30 others - and as such is subject to the risks of multiple
comparis ons between groups. This risk is exacerbated by sub-analysis according to stratification
(total of 60 comparisons between groups).
In order to reso lve this issue of caesarean section risk with oral miscprostol. it would
have been necessary to design the trial with a difference in caesarean sectio ns as the primary
outcome measure. In orde r to detect an increase of 5% in the caesarean section rate, such a study
would have required a sample size of 1106 per arm. However , it must be borne in mind that this
trial represents the .ti.rlI study of the use of this drug for labour induction. It would appear
inappropriate to subject 1106 patients to an intervention. with absol utely no evidence as to
whether or not it is effective. Hence it was felt that the design described in this thesis was the
most appropriate in the exploratory evaluation of this novel technique. Clear ly, however, the
completion of a small exploratory randomised trial should not be sufficient to allow widespread
acceptan ce of a new interven tion, particularly in the vital area of human labour and delivery.
This theoretica l biological risk (i.e. misopros tol induced uterine hype rstimu lation, subsequent
fetal asphyxia and/or caesarean section) is, in the author's opinion, the most important
unreso lved question with regard to misoprostol.' s use for labour induct ion, whether administered
orally or vaginally .
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5.2 Stre ngths and Weaknesses:
Consideration of the strengths of a study involves two principle areas. Firstly, is
the question an important one, and secondly how well is the question answered? With
regard to the clinical importance of this study, the following points may be made. The
induction rate is growing in Canada. resulting in the exposure of many healthy women
and their fetus/neonates to induction agents. However, all of the presently available
agents are expensive and none are free of side effects. Furthermore in an occasional
patient. all the presently available agents will fail to induce labour. There is, therefore.
the need to continue the search for an optimal labour induction regime and to continue to
provide information on all the agents in the induction armamentarium. Any potential side
effects. or risks. to this young healthy population must be fully exposed. As misoprostol
has been shown to be an effective induction agent, therefore. any research on it' s
application is important. This perception of its clinical importance is widespread. A
med-line search at the time of rewriting this thesis (August 1998) reveals that there have
been 32 randomized trials of standard prostaglandins versus misoprostol in the 1997 to
1998 period alone. During the same time period. there have been IlQ reports of trials
comparing standard prostaglandins to any other agents.
The second area in discussion of a studies' strength centres around how well the
question is answered. This study complies well with the principles for conducting and
reporting a randomised trial of a new intervention. The study population and the venue
for the trial are carefully described. All patients who entered were randomised. All
subjects who entered were cared for according to randomisation and they were reported
on fully at completion. All relevant outcomes were prospectively evaluated and reponed.
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Uniquely, amon g studies of the labour induction, we reported on patients ' satisfaction
with their birth experience. We designed a lrial with the power to detect the delta which
our centre consi dered to be importan t, and defended that delta in the text. We avoided
misi nterpre tation o f the data by setti ng a very low p-value for secondary ou tcome
analysis ; avoiding over comparison between groups and setting a l} of 5. Finally. we
anem pted not to overstate the case in favour o f 01111misoprostol and pointed to the need
for further research . before il could be recommended for general use.
With regard to weaknesses of the study. these primari ly concern the followin g
Firstly, as this was the first ever use of this agent, we felt that blindin g was
inappropriate. This is of importance. as obstetrical care with respect to the co-
interventions of oxytoci n and artifici al rupture of membranes, was not rigid ly mandated
in either arm. A biased caregiver . there fore could offer these co-intervent ions more
aggress ivel y in his/h er favoured ann. thereby confounding lhe results. As all care givers
were asked to give the optimal obstetric care to any and all patients. we hoped to
minimise this risk. Clearly however. funher studies should be fully blinded. In such
future studies a more didactically defined "standard care" protocol . with less
heterogeneity of standard options would also be helpful. A double-blinded trial of oral
miscprostcl versus vaginal prostin gel with standardised ruptur e o f membran es and
oxytocin administration in both arms would be an example of such a study.
Apart from the weaknesses of unblinding and standard group heterog enei ty, the
other leading weakn esses o f the study are as follows. Firstly. non-participants were not
documented, or described . Neonatal umbilical cord pH and patient questionnai res were
not obtained in all cases. The delta was subjecti vely chosen, wilh no consumer input.
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The sample size is insufficient to form conclusions regarding maternal risks - specifically
caesarean section risk Q.[ fetal risks specifically uterine hypersrimulation induced hypoxic
asphyxia.
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5.3 Conclusions:
ln this 273 patient randomized controlled clinical trial no significant differences in
effectiveness or safety were found between oral misoprostol and standard labour induction
agents. Oral misoprcstc t was very well tolerated orally. Responding parturients indicated their
preference for an oral rather than vaginal route of administration of induction medications. More
studies are needed to confirm effectiveness. and 10 evaluate further the issues of maternal side
effects and neonatal safety. Optimal dosage and frequency of administration also need to be
resolved. However. based on the study reported in this thesis. it does appear that oral
misoprostol may bean effective and safe induction agent, and may be the first effective induction
agent that is well tolerated orally because of its minimal gastrointestinal side effects.
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5.4 Futu re Studie s
Since the completion of the data analysis for this trial there have been further studies
demonstra ting again the effectiveness ofmi soprosto l in the induction of labour at term . The
question of whether or not there is enough evidence for the widespread use of misoprostol for
induction of labour at term as cited by clinical trial protocols remains controversial. If ora l
misoprostol is to become widespread in its usc in routine clinical induction of labour, this will
result from one of three developments. Firstly, as evidence accumulates, there might simply be a
generalized consensus that this medication represents a reasonable option for the induction of
labour at term. Secondly. a large meta-analysis and overview of all the randomized trials
performed to date might provide evidence to justify a change in accepted practice. The third
possibili ty is that ofa large multi-centre trial. Ideally this trial would be a double-blinded
random ized controlled trial. with sufficient power to look not only at length of time from
induction oflabour to delivery, but also to evaluate substantive and meaningful outcomes, such
as frequency of caesarean sections and neonatal asphyxia.
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APPENDIX I Bishop Scor~
Points Award
Criteria
0 I 2 3
Cervical Dilalation (em) 0 \ -2 3-' 5-.
Cervical effacemenl (%) 0 -30 40 - 40 60-'70 S 80
Cervical censlstency Firm medium son
Cenrical position Posl erior eeet ra l aa tertor
Slation
(10 relatioa 10 (be spin") 3ema bo\'t zcm abeve I- Oem above t c z em betow
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Consent Titl e:
Investigators :
Appendix II
Randomized Tri al Compa ring Or al Misoprostol v ersus
Standa rd Pro tocol for Lab our Induction
On . Rol')' Wind rim. David Young an d William Mundie
You are being asked to participate in a research study. Participation in the study is
entirely voluntary. You may freely decide not to participate or 10 withdraw from the study at any
time without affecting your normal treatment. Confidentiality of information concerning
participants will be maintained by the investigators, The investigators will be available should
you have any problems or questions regarding this study.
Descrip tion and Back ground Inform ation :
I understand I have been scheduled for induction of labour. I am aware that standard
treatment usually involves the intravenous administration of a substance called oxytocin plus
cervicaUvaginal application of prosraglandin-comaining cream for cervical ripening if necessary.
I know that the procedure usually involves an artificial rupture of membranes of "breaking of my
water",
Prostaglandins. although primarily used as cervical ripening agents, also stimulate labour,
These medication can be administered orally or vaginally.
This trial will attempt to decide if administration of misoprostol orally >a prostaglandin
not widely used for induction of labour, but often used for gastrointestinal disorders . will safely
decrease the time required from start of drug administration to delivery,
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If I choose to enter this study, I will be randomized (chosen as if by flipping a coin) into
one of two groups. One group will receive the standard treatment as described above while the
other group will receive misoprostol orally. There would be no additional examinations or blood
tests, other than those needed for standard labour induction. After delivery, my chart will be
reviewed by the investigators for information regarding my delivery and baby. I understand that
I will remain under the care of my physician who will manage my labour/delivery as deemed
necessary.
Alternat iye Tre atm ent s'
The alternative should I choose not to enter the study, would be induction via the
standard method employing oxytocin (see above).
Voluntary Participation '
I have discussed the information provided with my physician and he/she has answered
any questions about my care/treatment that I have.
Confident ialitY/Access to Medica! Recgrds'
I understand that records concerning my labour. delivery and hospital stay will be
reviewed and I give my permission for this. No records bearing my name will be provided to
anyone other than the investigators in this study. I will not be identified in any publications in
any manner.
Patient Signature Date _
Investigator Signature Date _
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ORAL CYTOTEC STUDY
Guide lines:
1. Elig ible patien ts are those book ed for induction with no contrain dication (e.g. previous
caesarean sec tion. severe lUGR. etc) .
2. All eligible pat ients to be counselled by attending physician and/or resident prior to signing
co nsent. Ifno one is available please call Dr. Windrim [0 counse l the pa tient.
3. After enrolling pat ient should be assi gned to PROM or intact membrane group .
4. Bishop Score should beperformedprior to openingenvelope.
5. Please slug all forms with the addressograph. except the questionnaire. which should be
given to the pat ient.
6. Medications should be judged al the time of adm inistrat ion and not pre-ord ered . so tha t
there is an individu al order for each Cytc tec. etc. given.
7. PO Cytotec is to be given every four (4) hours as needed . The first two dos ages sho uld be
50 Ilg misop rostol. If there is no change in the cervix, or no labour , this may be
increas ed 10 100 IJ.gfor subseq uent doses at the order of the attending physician. Under
no circumstances should dos ing higher than 100 IJ.gmisoprostol q4h be used .
8. [f there are any questions pleas e call Dr. wi ndrim:
omce ~
Pag er - _
Home- _
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Group
Chart II
A,_
Gravida.Para
Gestation (days)
Bishop - Position
- c cnsrsrence
- Effacement
- Ditanon
- Starion
s Dcses cf Narcotic
Epidural
PG #ofDoses
Mg.PG
Mg. Miscprcs tol
Oxvtccm s n nnutes
lodicauon fcrlnducricn
Typc of Deli...ery : SVD Vacuum forc eps LSCS
Indication for OR: NRT FTP None
Episiotom y: Nil Lat. Midline
Laceratio ns
Manual Removal of Placenta
Blood Loss : Nonnal cr
Scalp pH
Side Effects: Nausea Vomiting Diarrhoea
Questionnaire Sent _ Yes _No
75
NAME
GRACE #
Hdays Mom
# days Baby
/I days temp> 38.5 Mom
# days temp > 38.5 Baby
1# daystemp< 36.5
Dextrcstick
1# Pelvic exams
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POST· PARTUM MISOPROSTOL STUDY SATISFACTION SURVEY
Please rate the rollowing sta tements on the basis or stro ngly agr ee == 10 and str ongly disagree " 1
I was very satisfied with the care we
received during labour and delivery.
1 23 456 7 89 10
2. Sufficient attention was paid to the safely 1 2 3 4 6 7 8 9 10
of mother and baby during labour and delivery.
3. The staff gave us all the care and attention 1 2 3 4 6 7 8 9 10
they could during labour and delivery.
4. Some unnecessary interventions were carried out 1 2 3 4 6 7 8 9 10
on mother or baby during labour and delivery.
5.
6.
Our wishes were always respected during
labour and delivery.
I feel happy about this labour and delivery
experience.
12 34 678910
1 2 456 78910
7. I felt in control of what happened during
labour and delivery.
8. I felt some mistakes were made in the care
received fromthe staff during labour and
delivery.
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1 23 4 5 67 8 9 10
1 2 3 4 5 6 7 8 9 10
9. If the staffhad been more capable during
labour and deli very I would have been
happier with the care received.
1 2 3 4 6 7 8 9 10
10. I would be felling better now if the staff
had been more considerate during labour
and delivery .
It . The nurse gave us all the care and attention
I wanted durin g labour and delivery .
12. The doctor gave all the attention needed
during labour and deli very.
13. I would have liked the staff to have responded
to me differently during labour and delivery .
14. Sufficient attention was paid to comfort
during labour and deli very .
15. I would have liked the managementof labour
and delivery to have been done differently.
16. There was too much equipment used during
labour and delivery .
17. The staff weresometimes rude to me during
labour anddelivery .
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1 23 4678910
1 2 3 4 6 7 8 91 0
1:2 .. 5 6 7 8 9 10
I :2 3 " 6 7 8 9 10
12 456789 10
1 2 34 6 7 8910
1 2 3 4 5 6 7 8 9 10
1 23456 78910
18. The re were too man y staff or studen ts invo lved I , J 4 5 6 7 8 9 10
in the labour and del ivery .
19. Staff treated meas iflhis wasjust onemore I 2 3 4 5 6 7 8 910
del ivery .
20. The staffhelped meto feel like thiswasa I , J 4 6 7 8 910
very special event.
21. The appropriate amoun t of equip ment was use d I , 3 4 6 7 8 q 10
to monitorthe labour and delivery.
22. Therewereoccasionswhennooneexplained to I 2 3 4 6 7 8 9 10
me what was going on.
23. Therewereunnecessaryrestrictions on mothers I , J 4 6 7 8 9 10
walking around during labour.
24. The mostcomfortable position was used for the , z J 4 5 6 7 8 910
actual delivery.
25. The thingsdone to the baby immediately after I 2 3 4 5 6 7 8 9 10
birth ....'ere all necessary .
26. I he ld the baby as soon as I wanted. I 2 3 4 5 6 7 8 910
27. They triedto delivery the placenta 100 I 2 J 4 5 6 7 8 9 10
quickly .
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28. I was givenall the information neededabout I 2 J 4 5 6 7 8 910
progressinlabour.
29. The nursewaswithme as muchas Iwanted. 1 2 3 4 5 6 7 8 9 10
30. l saw thedoctoras often as I wanted. 1 2 3 4 5 6 7 8 9 10
31. Iwassatisfiedwiththeway painwas 1 2 3 4 6 7 8 9 10
relievedduringdelivery.
32. I was dissatisfied withthe way painwas 1 2 3 4 6 7 8 9 10
relievedduring delivery.
33. Thereweretoomanyvaginalexaminations. 1 2 3 4 6 7 8 91 0
34. Ourbirth planswereignored. 1 2 3 4 5 6 7 8 9 10
35. Recoverytime in labouranddelivery . 1 2 3 4 6 7 8 9 10
36. Thenursemadethe labouranddeliverya 1 2 3 4 5 6 7 8 910
betterexperience.
37. I wish. aJl doctorswere as good as ours. 1 2 3 4 5 6 7 8 9 10
38. The doctormadethelabour anddelivery 1 2 3 4 5 6 7 8 91 0
a betterexperience.
39. Ididnot experience diarrhoeaduringmy 1 2 3 4 5 6 7 8 9 10
induction, labouranddelivery.
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40. I did not experience stomach cramps during
my induction. labour and delivery.
4 1. I would prefer an oral to vaginal medication
to "ri pen" my cervix.
42. I would be prepared (0 spend an extra _ hours
between beginning the ripening process and
delivery. in order to have the medications orally
instead of vaginally, Choose number of hours:
8\
1 23 4 5 67 8 9 10
I 2 3 4 5 6 7 8 9 10
11 18 24
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